DermWire | Newest Articles http://practicaldermatology.com/dermwire/ Newest Articles en-us Wed, 17 Oct 2018 11:53:23 GMT Wed, 17 Oct 2018 11:53:23 GMT DermWire Krystal Biotech: Positive Interim Results in Phase 1/2 Trial of KB103 http://practicaldermatology.com/dermwire/view.asp?url=krystal-biotech-positive-interim-results-in-phase-12-kb103-trial Krystal Biotech, Inc. has announced positive interim results from its ongoing placebo-controlled Phase 1/2 clinical trial of KB103. Two adult Recessive Dystrophic Epidermolysis Bullosa (“RDEB”), NC1[+] patients aged 35 and 28 years old have completed treatment with topical KB103 to date. The patients were re-dosed during the study. In each patient, two wounds with an approximate surface area of 10 cm2were randomized to receive either topical KB103 or placebo (for a total of 4 woun… Mon, 15 Oct 2018 04:00:00 GMT Lumenis Introduces SPLENDOR X, New Laser Hair Removal Solution http://practicaldermatology.com/dermwire/view.asp?url=lumenis-introduces-splendor-x-new-laser-hair-removal-solution Lumenis Ltd. has launched SPLENDOR X, the first solid state laser system equipped with the unique BLEND X technology for fast and effective hair removal and skin solutions. The technology was showcased for the first time at the 2018 American Society of Dermatological Surgery (ASDS) in Phoenix this month. SPLENDOR X is suitable for a wide range of hair removal procedures. BLEND X permits bilateral laser emission of Nd: YAG (1064nm) and Alexandrite (755nm) wavelengths, synchronized to fire wit… Mon, 15 Oct 2018 04:00:00 GMT Music City SCALE: Registration Open; New Website Launches http://practicaldermatology.com/dermwire/view.asp?url=music-city-scale-registration-open-new-website-launches Registration is now open for Music City Scale on the meeting's newly redesigned website. The website features new details about the meeting, scheduled May 9-11, 2019 at Music City Center in Nashville. "We are gearing up for SCALE 2019, one of the premier dermatology and cosmetic meetings in the US," says meeting co-director, Michael H. Gold, MD. "We have opened up registration for SCALE 2019, to be held from May 9-11, 2019 at our new web site ScaleMusicCity.com. We encourag… Mon, 15 Oct 2018 04:00:00 GMT ASDS Announces 2018 President’s Award Recipients http://practicaldermatology.com/dermwire/view.asp?url=asds-announces-2018-presidents-award-recipients In her final act as president this week, Lisa M. Donofrio, MD, recognizes four members of the American Society for Dermatologic Surgery (ASDS) with the President’s Award at the Society’s Annual Meeting. “One of the wonderful gifts about being president of an organization like this is the opportunity to recognize some of the special people and organizations who have helped the Society thrive,” Dr. Donofrio says. “I am fortunate to have the privilege of recognizing… Thu, 11 Oct 2018 04:00:00 GMT Cellulite Reduction Seen With Cellfina Lasts Five Years http://practicaldermatology.com/dermwire/view.asp?url=cellulite-reduction-seen-with-cellfina-lasts-five-years One Cellfina treatment improves the appearance of cellulite on the thighs and buttocks for five years, according to new data presented by Merz at the Annual Meeting of the American Society for Dermatologic Surgery (ASDS) in Phoenix, AZ. This new data builds upon Cellfina’s duration of effectiveness, which was previously three years - the longest FDA clearance for a cellulite treatment. Of the patients who completed the five-year follow up, evaluators rated 100 percent of the patients… Thu, 11 Oct 2018 04:00:00 GMT Pre-conditioning Added to Sebacia Microparticles Enhances Outcomes http://practicaldermatology.com/dermwire/view.asp?url=pre-conditioning-added-to-sebacia-microparticles-enhances-outcomes Using pre-conditioning in conjunction with Sebacia Microparticles for treatment of acne leads to enhanced outcomes, new data suggest. In fact, results from a real-world, pre-conditioning registry trial in Europe demonstrate that the combination of pre-conditioning followed by Sebacia Microparticles leads to an average 79% improvement in facial acne through six months of follow-up. For the ongoing single-arm registry study being conducted at nine commercial practices in Europe patients (n=71… Thu, 11 Oct 2018 04:00:00 GMT Endo Presents Data on the Perception and Measurement of Cellulite Severity at ASDS Meeting http://practicaldermatology.com/dermwire/view.asp?url=endo-presents-data-on-the-perception-and-measurement-of-cellulite-severity-at-asds-meeting The new Clinician Reported Photonumeric Cellulite Severity Scale (CR-PCSS) is a reliable tool for evaluating cellulite severity of the buttocks and thighs and correlates well with the Patient Reported Photonumeric Cellulite Severity Scale, according to research presented by Endo International plc. at the Annual Meeting of the American Society for Dermatologic Surgery (ASDS) in Phoenix, AZ. "It is important that healthcare providers and their patients have a reliable tool for evaluating c… Thu, 11 Oct 2018 04:00:00 GMT Study: Positive Safety and Tolerability Results for Ortho Dermatologics' Altreno for Acne http://practicaldermatology.com/dermwire/view.asp?url=study-positive-results-for-ortho-dermatologics-altrenos-safety-and-tolerability-for-acne Ortho Dermatologics shared results of two identical Phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel group studies examining the efficacy and safety of Altreno (tretinoin) Lotion, 0.05%, the first formulation of tretinoin, a retinoid, in a lotion indicated for the topical treatment of acne vulgaris in patients 9 years of age and older. The FDA approved the New Drug Application for Altreno Lotion on Aug. 24, 2018. Results were publishedd in the Journal of Drugs in Der… Thu, 11 Oct 2018 04:00:00 GMT Galderma Ups Its Aesthetic RD Game http://practicaldermatology.com/dermwire/view.asp?url=galderma-ups-their-aesthetic-r--d-game Galderma Laboratories, L.P. is initiating six new Phase III and IV U.S. aesthetic clinical trials. The six newly initiated studies include three pivotal trials evaluating XpresHAn Technology products; two studies for Dysport evaluating patient satisfaction and duration; and one study focusing on the unique properties of Sculptra Aesthetic (injectable poly-L-lactic acid). The company's R&D expansion also includes a significant increase in the number of women selected as clinical inv… Thu, 11 Oct 2018 04:00:00 GMT AlmirallShare Issues Call for Proposals http://practicaldermatology.com/dermwire/view.asp?url=almirallshare-issues-call-for-proposals Almirall is seeking to find novel targets and concepts in the treatment of dermatological diseases. The company’s AlmirallShare open innovation platform is calling for proposals from October 10, 2018 to February 28, 2019 from universities, research centers, start-ups, biotechs and pharma companies all over the world with an interest in pharmaceutical R&D. Targets of interest may be proteins or nucleic acids whose function can be modulated by a small molecule or biological therapy t… Wed, 10 Oct 2018 04:00:00 GMT Topix Pharmaceuticals Introduces Its New Backbar Line http://practicaldermatology.com/dermwire/view.asp?url=topix-pharmaceuticals-introduces-its-new-backbar-line Topix Pharmaceuticals, Inc. is rolling out its Backbar Line, a collection of 10 professional products that allows physicians to use their own branding. Only available for sale direct to office, the line is designed to support procedures and non-invasive treatments. The collection features: Gentle Antioxidant Soothing Cleanser: The soap-free formula gently cleanses and soothes with antioxidants and botanicals like pro vitamin B, and chamomile and cucumber extracts. Clarifying… Tue, 9 Oct 2018 04:00:00 GMT Alastin Skincare’s Latest Product May Become Body Contouring Procedures’ New BFF http://practicaldermatology.com/dermwire/view.asp?url=alastin-skincares-latest-product-may-be-body-contouring-procedures-new-bff Alastin Skincare, Inc. is launching TransFORM Body Treatment with TriHex Technology at the upcoming American Society for Dermatologic Surgery (ASDS) Annual Meeting in Phoenix. When this product is applied after non-surgical body fat reduction and energy-based body skin tightening procedures, it helps accelerate outcomes by supporting the body’s natural repair processes. It also helps to support the production of elastin and collagen to enhance the results of body skin tightening procedu… Tue, 9 Oct 2018 04:00:00 GMT Online Care May Be As Effective as In-Person Care for Psoriasis http://practicaldermatology.com/dermwire/view.asp?url=online-care-may-be-as-effective-as-in-person-care-for-psoriasis Teledermatology may be as effective as seeing a doctor in person when it comes to improving the symptoms of psoriasis, according to a new study in JAMA Network Open. “Patients with chronic skin diseases need ongoing care, and depending on where they live, their access to dermatological care can be variable,” says the study’s lead author April Armstrong, MD, MPH, professor of dermatology (clinical scholar) and associate dean for clinical research at the Keck School of Medicin… Tue, 9 Oct 2018 04:00:00 GMT Ortho Dermatologics Receives Tentative FDA Approval for Bryhali for Plaque Psoriasis http://practicaldermatology.com/dermwire/view.asp?url=ortho-dermatologics-received-tentative-fda-approval-for-bryhali-for-plaque-psoriasis The FDA has provided tentative approval of the New Drug Application for Bryhali (halobetasol propionate) Lotion, 0.01%, for the topical treatment of plaque psoriasis in adult patients. Bryhali Lotion is a new potent to superpotent corticosteroid that contains 0.01 percent halobetasol propionate in a novel vehicle lotion. Its safety has been established in clinical trials with dosing for up to eight weeks with no increase in epidermal atrophy. The final FDA approval for Bryhali Lotion is pending … Mon, 8 Oct 2018 04:00:00 GMT EPI Acquires Rights to Cloderm Cream from Promius Pharma http://practicaldermatology.com/dermwire/view.asp?url=epi-acquires EPI Health has acquired the rights rights to Cloderm® (clocortolone pivalate) Cream, 0.1% and its authorized generic from Promius Pharma, LLC, a wholly owned subsidiary of Dr. Reddy's Laboratories, Ltd. Under the terms of the agreement, Promius Pharma is eligible to receive an upfront payment followed by future royalties as the consideration for Cloderm® Cream and its authorized generic in the United States, effective immediately. “We look forward to EPI cont… Fri, 5 Oct 2018 04:00:00 GMT ISDIN Launches Melatonik Nighttime Serum http://practicaldermatology.com/dermwire/view.asp?url=isdin-launches-melatonik-nighttime-serum ISDIN's Melatonik nighttime serum formulated with melatonin, bakuchiol (a natural antioxidant with retinol-like properties) and Vitamin C, is now available. It was developed to help skin recover from the day and prepare it to fight the stresses of tomorrow, ISDIN says. Melatonik stimulates the skin’s natural antioxidant defenses, repairing environmental stress and damages from the previous day and supporting healthy, younger looking skin. Melatonik includes: Melatonin: A… Fri, 5 Oct 2018 04:00:00 GMT Acne Stigma Linked to Lower Overall Q of L http://practicaldermatology.com/dermwire/view.asp?url=acne-stigma-linked-to-lower-overall-q-of-l Acne patients perceived social stigma negatively affects their quality of life, according to a new study from the University of Limerick. In the survey of 271 people with acne, those whose negative perceptions of how society viewed their appearance had higher psychological distress levels and further physical symptoms such as sleep disturbance, headaches and gastrointestinal problems. Females in the study reported greater impairment of life quality and more symptoms than males. Acne sever… Wed, 3 Oct 2018 04:00:00 GMT FDA Approves Paratek's Nuzyra http://practicaldermatology.com/dermwire/view.asp?url=fda-approves-parateks-nuzyra The FDA has approved Paratek Pharmaceuticals, Inc's Nuzyra (omadacycline) for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute skin and skin structure infections (ABSSSI). Nuzyra, a modernized tetracycline, is a once-daily IV and oral antibiotic that exhibits activity across a spectrum of bacteria, including Gram-positive, Gram-negative, atypicals, and drug resistant strains. The company plans on making Nuzyra available in the first quarter 2019. &ldquo… Wed, 3 Oct 2018 04:00:00 GMT Veloce BioPharma Announces Positive Phase 2b Study Results for VBP-926 for Chemotherapy-Associated Paronychia http://practicaldermatology.com/dermwire/view.asp?url=veloce-biopharma-announces-positive-phase-2b-study-results-for-vbp-926-for-chemotherapy-associated-paronychia Veloce BioPharma, LLC, a clinical-stage biopharmaceutical company dedicated to developing topical therapeutics for unmet needs in dermatologic and ophthalmic diseases, shared positive results of its Phase 2b study of dilute povidone-iodine in a novel DMSO solvent system for the topical treatment of chemotherapy-associated paronychia, or painful and inflamed nail units resulting as a side effect of chemotherapy. The multicenter, randomized, double-blind, vehicle-controlled Phase 2b study was d… Wed, 3 Oct 2018 04:00:00 GMT Allergan’s New Campaign Urges Consumers to Just Juvéderm It http://practicaldermatology.com/dermwire/view.asp?url=allergans-new-campaign-urges-consumers-to-just-juvderm-it Allergan plc is rolling out a new Juvéderm advertising campaign that aims to make this family of fillers a household name. Comprising a modernized logo, a bright, poppy color scheme, an edgy soundtrack and robust social media component, Juvéderm It is the first new advertising campaign in three years. "Healthcare providers already know that Juvéderm is the No. 1 selling collection of dermal fillers, but consumers tend to think about 'fillers' as a general… Wed, 3 Oct 2018 04:00:00 GMT Dermira’s Qbrexa Cloth Now Available for Primary Axillary Hyperhidrosis http://practicaldermatology.com/dermwire/view.asp?url=dermiras-qbrexa-cloth-now-available-for-primary-axillary-hyperhidrosis Dermira, Inc.'s Qbrexa (glycopyrronium) cloth is now available for prescribing to treat primary axillary hyperhidrosis. The new therapy is available in retail and community pharmacies nationwide. In June 2018, QBREXZA, a once-daily, prescription anticholinergic, was FDA approved to treat adult and pediatric patients 9 years of age and older living with this chronic, medical skin condition. “People living with primary axillary hyperhidrosis often report feelings of isolation, and str… Wed, 3 Oct 2018 04:00:00 GMT LEO Science Tech Hub and Epicore Biosystems to Explore Wearable Skin Sensors to Improve Dermatologic Treatment Regimens http://practicaldermatology.com/dermwire/view.asp?url=leo-science--tech-hub-and-epicore-biosystems-to-explore-wearable-skin-sensors-to-improve-dermatologic-treatment-regimens LEO Science & Tech Hub has established a new partnership with Epicore Biosystems focused on exploring the use of a non-invasive, wearable sweat sensor to measure prognostic biomarkers in real time, monitor patient response and inform treatment decisions. The initial project will include a proof of concept study in collaboration with engineers and dermatologists at Northwestern University’s Center for Bio-Integrated Electronics and Feinberg School of Medicine’s Department of Derma… Tue, 2 Oct 2018 04:00:00 GMT Seysara: Oral Antibiotic is First Approved for Dermatology in 40 Years http://practicaldermatology.com/dermwire/view.asp?url=seysara-oral-antibiotic-is-first-approved-for-dermatology-in-40-years Seysara (sarecycline), a new, first in class tetracycline-derived oral antibiotic, is now approved for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older. Almirall, which recently acquired Seysara from Allergan, plans to launch the drug in January 2019. Seysarais an oral tablet that is taken once daily with or without food. It has proven significant reduction of inflammatory lesions as early as three weeks after start of … Tue, 2 Oct 2018 04:00:00 GMT Ortho Dermatologics’ Bryhali Lotions Performs Well in Two Phase 3 Psoriasis Trials http://practicaldermatology.com/dermwire/view.asp?url=ortho-dermatologics-psoriasis-drug-bryhali-performs-well-in-two-phase-3-trials Two Phase 3 randomized controlled trials show that Bryhali (halobetasol propionate) Lotion, 0.01%, an investigational potent to superpotent corticosteroid in the treatment of moderate-to-severe plaque psoriasis, is effective and well-tolerated. Bryhali Lotion has a Prescription Drug User Fee Act (PDUFA) action date of October 5, 2018. In the studies, Bryhali Lotion was consistently more effective than vehicle in achieving treatment success, which was defined as at least a two-grade improve… Tue, 2 Oct 2018 04:00:00 GMT Is Teen Acne a Sign of Future Financial Success? http://practicaldermatology.com/dermwire/view.asp?url=is-teen-acne-a-sign-of-future-financial-success The love of books, the need for glasses and high intelligence are traits found among the top earners in many fields across the country, and now, a Ball State University researcher suggests that teen acne may also be on this list. In his study, “Do Pimples Pay? Acne, Human Capital, and the Labor Market Abstract,” Erik Nesson, a Ball State economics professor, found that having acne is positively associated with overall grade point average in high school, grades in high-school Engli… Tue, 2 Oct 2018 04:00:00 GMT